These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7654894)

  • 1. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
    Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
    Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
    Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
    J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
    Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
    Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.
    Yu A; Baker JR; Fioritto AF; Wang Y; Luo R; Li S; Wen B; Bly M; Tsume Y; Koenigsknecht MJ; Zhang X; Lionberger R; Amidon GL; Hasler WL; Sun D
    Mol Pharm; 2017 Feb; 14(2):345-358. PubMed ID: 28009518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
    Sciarretta G; Furno A; Mazzoni M; Ferrieri A; Malaguti P
    Scand J Gastroenterol; 1993 Sep; 28(9):783-5. PubMed ID: 8235433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.
    Saverymuttu SH; Gupta S; Keshavarzian A; Donovan B; Hodgson HJ
    Digestion; 1986; 33(2):89-91. PubMed ID: 3512352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].
    Keller J; Goebell H; Klotz U; Layer P
    Med Klin (Munich); 1998 May; 93(5):294-9. PubMed ID: 9630813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
    Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
    Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery and fate of oral mesalamine microgranules within the human small intestine.
    Layer PH; Goebell H; Keller J; Dignass A; Klotz U
    Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa.
    Rasmussen SN; Lauritsen K; Tage-Jensen U; Nielsen OH; Bytzer P; Jacobsen O; Ladefoged K; Vilien M; Binder V; Rask-Madsen J
    Scand J Gastroenterol; 1987 Sep; 22(7):877-83. PubMed ID: 3313678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
    Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
    Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.